Orchard Therapeutics
AcquiredCorporateBiotech & Life SciencesBritish
Gene therapy company developing ex-vivo autologous haematopoietic stem cell gene therapies for rare neurometabolic and immune disorders. Acquired by Kyowa Kirin in January 2024 for approximately $387 million, with operations continuing from its London and Boston facilities as a Kyowa Kirin subsidiary.